Changlu Liu

Title: Changlu Liu: Innovator in Peptide Antagonists and Receptor Modulators

Introduction

Changlu Liu is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of peptide antagonists and receptor modulators. With a total of 8 patents, Liu has made remarkable strides in understanding and manipulating G protein-coupled receptors (GPCRs), which play a crucial role in various biological processes.

Latest Patents

Among his latest patents, Liu has developed a chimeric peptide antagonist for GPCR135 and GPCR142. This chimeric polypeptide, R3(BΔ23-27)R/I5, is recognized for its high-affinity antagonistic properties over LGR7. Additionally, he has created methods for identifying modulators of GPR81 receptors, utilizing complexes of GPR81 receptor components and ligand components, such as L-lactate or GHB, as assay reagents for screening potential modulators of GPR81 receptor activity.

Career Highlights

Liu has worked with notable companies in the pharmaceutical industry, including Janssen Pharmaceutica NV and Ortho-McNeil Pharmaceutical Corporation. His work in these organizations has allowed him to apply his innovative ideas in practical settings, contributing to advancements in drug development and therapeutic strategies.

Collaborations

Throughout his career, Liu has collaborated with esteemed colleagues, including Timothy W. Lovenberg and Pascal Bonaventure. These partnerships have fostered a collaborative environment that enhances research and innovation in the field.

Conclusion

Changlu Liu's work exemplifies the impact of innovative research in the pharmaceutical industry. His patents and collaborations continue to influence the development of new therapeutic approaches, showcasing the importance of inventors in advancing science and medicine.